Status:
COMPLETED
Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.
Lead Sponsor:
59th Medical Wing
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to determine whether serum resistin levels in asthmatics are elevated. We will recruit subjects from the allergy/immunology clinic with a prior diagnosis of moderate to se...
Detailed Description
Resistin is part of the FIZZ (found in inflammatory zones) family of genes, and was first characterized in murine models where it has been extensively studied as a potential link between type II diabe...
Eligibility Criteria
Inclusion
- Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study.
- Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.
Exclusion
- Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.
- Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00339703
Start Date
November 1 2004
End Date
May 1 2006
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wilford Hall Medical Center
San Antonio, Texas, United States, 78236